A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

Northwestern Medicine scientists have identified the cellular mechanisms that cause immune cells to differentiate and ultimately lose function during viral infection, findings that could improve ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal ...

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...